Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

36P - Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: A real-world multi-center study


31 Mar 2023


Poster Display session


Bo Jia


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


B. Jia1, J. Zhao2, B. Jin3, F. Zhang3, S. Wang3, L. Zhang3, Z. Wang4, T. An4, Y. Wang4, M. Zhuo4, J. Li4, X. Yang4, S. Li4, H. Chen4, Y. Chi4, J. Wang1, X. Zhai4, Y. Tai4, Y. Liu4, G. Guan4

Author affiliations

  • 1 Beijing/CN
  • 2 Beijing Cancer Hospital, Beijing/CN
  • 3 The First Hospital of China Medical University, Shenyang/CN
  • 4 Peking University Cancer Hospital and Institute, Beijing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 36P


BRAF mutation is one of the targetable oncogenic driver mutations in non-small-cell lung cancer (NSCLC). However, the prevalence, real-world treatments and clinical outcomes are rarely reported in Chinese BRAF-mutated NSCLC patients.


The next-generation sequencing (NGS) data of 137,798 Chinese NSCLC patients from the Lung Cancer Big Data Precise Treatment Collaboration Group (LANDSCAPE) project (Cohort I) were analyzed to derive the prevalence of BRAF mutations. We also retrospectively collected clinical and survival data of 129 advanced NSCLC patients with primary BRAF mutation from two centers between December 2015 and September 2022 (Cohort II). Baseline characteristics, treatment pattern and outcomes were analyzed in Cohort II.


In Cohort I, 4409 patients (3.2%) were confirmed to harbor a BRAF mutation. BRAF V600E accounted for 28.7% of all BRAF mutation. In Cohort II, 62% (80/129) were BRAF V600 mutation with median age of 63.0 years. Of 99 patients who receive NGS, 79 (79.8%) patients had concomitant mutations, with TP53 of the highest incidence (33.3%). For patients received first-line dabrafenib plus trametinib (dab-tram) (N = 38), the median progression-free survival (PFS) was 25.0 months (95%CI: 13-NA), which is significantly longer than chemotherapy (N = 38, mPFS 8.4 months, 95%CI: 6.3–19.2, P = 0.023) and other regimens (N = 11, mPFS 8.0 months, 95%CI: 7.8-NA, P = 0.046). A numerically longer mPFS was also observed with dab-tram versus immunotherapy based therapy (N = 22, mPFS 11.4 months, 95%CI: 7.8-NA, P = 0.25). After applying inverse probability of treatment weighting (IPTW), the above differences still existed.


In the study with the largest sample size so for, 3.2% of Chinese NSCLC patients were observed to have BRAF mutations. The more favorable PFS benefit demonstrated by first-line dabrafenib plus trametinib compared with all other therapy regimens indicates the optimal treatment choice for Chinese BRAF-mutated NSCLC patients.

Legal entity responsible for the study

Peking University Cancer Hospital.


Science Foundation of Peking University Cancer Hospital.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.